Ocugen Shares Gain After Its Partner’s COVID-19 Vaccine Shows Effectiveness Against Multiple Variants
See also: How to Make Money from Home During COVID-19 Quarantine
Moderna Inks Supply Pact Of 500M COVID-19 Vaccine Doses To COVAX Effort Starting Q4
Moderna Inc (NASDAQ: MRNA) has announced an agreement with vaccine promoter Gavi to supply up to 500 million doses of its COVID-19…
Denali-Biogen Parkinson’s Disease Candidate Shows Reductions In Biomarkers; Late Study To Begin By 2021 End
Denali Therapeutics Inc (NASDAQ: DNLI) has announced final results from Phase 1 and Phase 1b studies evaluating BIIB122/DNL151 Parkinson's disease. The drug…
Emergent BioSolutions Has Supply Of 60M Johnson & Johnson COVID-19 Vaccine Doses Awaiting Approval: Bloomberg
Emergent BioSolutions Inc (NYSE: EBS) has manufactured over 115 million doses of drug substance used in the Johnson & Johnson (NYSE: JNJ) COVID-19…
Two Doses Pfizer-BioNTech COVID-19 Vaccine Necessary To Generate Immune Response Against Variants, UK Study Show: Reuters
According to a U.K. study, a single dose of Pfizer Inc (NYSE: PFE) – BioNTech SE's (NASDAQ: BNTX) coronavirus vaccine may not generate a…
Novavax Secures Additional $147M From Warp Speed Program For COVID-19 Vaccine
According to an SEC filing, Novavax Inc (NASDAQ: NVAX) has received an additional $147.3M as part of Operation Warp Speed to…
Pfizer-BioNTech Bullish On COVID-19 Vaccine Trial Results In Infants By September: Reuters
BioNTech SE's (NASDAQ: BNTX) CEO Ugur Sahin says the company, along with its partner Pfizer Inc (NYSE: PFE), could have data from trials…
Teladoc Stock Plummets Facing Analyst Price Target Cuts After Wider Than Expected Q1 Loss
Teladoc Health (NYSE: TDOC) reported a wider than expected Q1 loss of $1.31 per share which missed the analyst consensus estimate of…
Moderna’s Flagship Venture Firm Cashed $1.4B From Stock Sale In Two Months: Forbes
Almost a decade ago, Flagship Pioneering, a VC fund run and majority-owned by Moderna Inc’s (NASDAQ: MRNA) chairman and co-founder, Noubar…
Zogenix’s Fintepla Associated With Improvements in Seizure Control, Executive Functions In Childhood Epilepsy Disorder
Zogenix Inc (NASDAQ: ZGNX) has announced new data showing the positive impact of treatment with Fintepla (fenfluramine) on everyday executive function for…